Acquisition of Lotus Pharmaceutical Shares Using a Treasury Share Disposal
First written in FY2019-Q2. 1 of 2 entries say "Achieved", first in FY2019-Q3. Latest entry: FY2019-Q3.
0 other companies' latest entry also says "Achieved".
- FY2019-Q3AchievedAnnual report
「Based on a resolution of the Board of Directors dated 20 March 2019, we disposed of 1,219,300 treasury shares through a private placement to Lotus Japan Holdings G.K. on 5 April 2019. As a result, during the nine-month cumulative period of the current consolidated fiscal year, capital surplus increased by ¥817 million and treasury stock decreased by ¥1,407 million. At the end of the current third-quarter consolidated accounting period, capital surplus was ¥5,841 million and treasury stock was ¥78 million.」
The private-placement disposal of 1,219,300 treasury shares for the purpose of forming a capital alliance with Lotus Pharmaceutical has been completed, and the accounting impact on capital surplus and treasury stock has also been disclosed. - FY2019-Q2First statedAnnual report
「At a meeting of the Board of Directors held on 20 March 2019, we resolved to dispose of treasury stock through a private placement to Lotus Japan Holdings G.K., a wholly owned subsidiary of Lotus Pharmaceutical Co., Ltd., for the purpose of forming a capital alliance with Lotus Pharmaceutical. The disposal was completed on 5 April 2019. Type and number of shares disposed of: common shares, 1,219,300 shares. Total disposal value: ¥2,225,222,500.」
To raise funds for the capital alliance with Lotus Pharmaceutical, the Company resolved to dispose of 1,219,300 common shares through a private placement, for a total value of ¥2,225,222,500, and completed the disposal. The structure involves acquiring newly issued shares of Lotus Pharmaceutical for an amount equivalent to the disposal proceeds.